2. The tests should match the specification and sensitivity of tests previously developed in AHDB funded projects for Mycosphaerella brassicicola, Albugo candida, Pyrenopeziza brassica and Peronospora destructor, in terms of spore thresholds for setting disease risk criteria.
3. Obligate pathogens will require validation using glasshouse raised inoculum for each pathogen and this inoculum will be used in antigen preparations.
4. Tests previously developed for Pyrenopeziza brassicae, Peronospora destructor are linked to an ELISA test format. These should be optimised within the first year so that LFD tests are available for all four tests in 2017.
5. The industry partner (Mologic) will undertake to optimise the provided antibodies (for the named tests) over the 2 years of the project to ensure that they are robust enough to provide a risk rating for the pathogens in LFD usage.